

## Processing your request...

### Dialog Index Results

Your select statement is 'S LAWSONIA(2N)INTRACELLULARIS  
(30N)(ANTIGEN OR IMMUNOGEN OR GROEL OR PROTEIN)' in databases  
ALLMEDPH.

☒ Select All

☒ Clear Selections




<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	2
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	4
<input type="checkbox"/> 50:	<u>CAB ABSTRACTS</u>	2
<input type="checkbox"/> 71:	<u>Elsevier Biobase</u>	2
<input type="checkbox"/> 73:	<u>EMBASE® (1974-present)</u>	1
<input type="checkbox"/> 76:	<u>Life Sciences Collection</u>	2
<input type="checkbox"/> 94:	<u>JICST-EPlus - Japanese Science &amp; Technology</u>	1
<input type="checkbox"/> 144:	<u>PASCAL</u>	1
<input type="checkbox"/> 155:	<u>MEDLINE® (1966-present)</u>	3
<input type="checkbox"/> 180:	<u>Federal Register</u>	1
<input type="checkbox"/> 348:	<u>European Patents Fulltext</u>	1
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	5
<input type="checkbox"/> 351:	<u>Derwent World Patents Index</u>	1
<input type="checkbox"/> 357:	<u>Derwent Biotechnology Abstracts</u>	1
<input type="checkbox"/> 399:	<u>CA SEARCH® - Chemical Abstracts® (1967- present)</u>	7
<input type="checkbox"/> 440:	<u>Current Contents Search®</u>	4
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1990-present)</u>	1

There are 17 databases matching your statement '**S  
LAWSONIA(2N)INTRACELLULARIS (30N)(ANTIGEN OR IMMUNOGEN  
OR GROEL OR PROTEIN)**'.

☒ **Select All**☒ **Clear Selections****Begin Databases****New Search****Sort Results**

---

© 2001 The Dialog Corporation

2/3,AB/1 (Item 1 from file: 5)

12891533 Biosis No.: 200100098682

**Interactions between dietary fibre, endo-parasites and Lawsonia intracellularis bacteria in grower-finisher pigs.**

**Author:** Pearce G P(a)

**Author Address:** (a)Department of Agriculture, University of Aberdeen,  
581King Street, MacRobert Building, Aberdeen, AB24 5UA:  
g.pearce@abdn.ac.uk\*\*UK

**Journal:** Veterinary Parasitology 87 ( 1 ): p 51-61 November, 1999

**Medium:** print

**ISSN:** 0304-4017

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Summary Language:** English

**Abstract:** Samples of faeces and feed were collected from grower and finisher pigs kept on 25 commercial breeder-finisher units in the West-Midlands region of England. Faecal samples were examined for parasite eggs (*Ascaris suis*, *Trichuris suum* and strongylid species) using faecal flotation; and for *Lawsonia intracellularis* bacteria using the polymerase chain reaction. Feed samples were subjected to proximate analysis for energy, protein and fibre content and enzymic colorimetry for levels of non-starch polysaccharides (NSPs). Characteristics relating to housing, feeding and dung disposal systems and husbandry practices were recorded for each farm and assessed for their association with the presence of parasites and *L. intracellularis* at the herd level. *Ascaris* eggs were identified in 8% of herds, *Trichuris* eggs in 20% of herds and in strongylid eggs (*Oesophogostomum* and/or *Hyoststrongylus*) in 44% of herds. *Lawsonia intracellularis* was detected in 15% of herds investigated. Herds positive for *Trichuris* and *Ascaris* had significantly lower levels of digestible energy and higher levels of neutral detergent fibre, total and insoluble NSPs in their diets than negative herds

( $p < 0.05$ ). Housing weaners on slatted floors was associated with a significant decreased risk of parasite infection in grower-finishers (odds ratio = 0.09,  $p = 0.04$ ) compared to housing on solid floors. The use of grower diets high in NSPs was associated with an increased risk of *Trichuris* infection (odds ratio = 27.6,  $p = 0.007$ ). There was also an association at the herd level between infection with *L. intracellularis* and the presence of *Trichuris* eggs (odds ratio = 17.43,  $p = 0.069$ ). It is concluded that control of dietary fibre intake (NSPs in particular) for growers and environmental hygiene (dung removal) for weaners appear to be the most important factors controlling parasite infection in grower-finisher pigs in the UK at present. The current move towards more straw based systems is thus likely to exacerbate the influence of these factors and is likely to result in increased parasite infection in grower-finisher pigs in the UK.

1999

Biosis Previews(R) (Dialog® File 5): (c) 2001 BIOSIS. All rights reserved.

---

2/3,AB/2 (Item 2 from file: 5)

12705973 Biosis No.: 200000459475

**Immunohistochemistry and polymerase chain reaction for the detection of *Lawsonia intracellularis* in porcine intestinal tissues with proliferative enteropathy.**

**Author:** Kim Junghyun; Choi Changsun; Cho Wan-Seob; Chae Chanhee(a)

**Author Address:** (a)Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, Suwon, Kyonggi Do, 441-744\*\*South Korea

**Journal:** Journal of Veterinary Medical Science 62 ( 7 ): p 771-773 July, 2000

**Medium:** print

**ISSN:** 0916-7250

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

**Summary Language:** English

**Abstract:** Detection method of *Lawsonia intracellularis* was studied in formalin-fixed paraffin-embedded intestinal tissues from 5 naturally infected pigs by immunohistochemistry with a monoclonal antibody against outer membrane protein of *L. intracellularis*. Warthin-Starry silver stain revealed clusters of argyrophilic, slightly curved rod-shaped organisms in the apical cytoplasm of enterocytes. Immunohistochemical staining with a *L. intracellularis*-specific monoclonal antibody confirmed the presence of the organism in the apical cytoplasm of hyperplastic enterocytes. The presence of *L. intracellularis* in the ileum of pig with proliferative enteropathy was confirmed by polymerase chain reaction (PCR) further on the basis of amplification of 319 base pair products specific for porcine *L. intracellularis* chromosomal DNA. Immunohistochemistry and PCR may be a complementary method to confirm the diagnosis of *L. intracellularis* infection in pigs.

2000

microscopy. Bacteria were further characterized by indirect immunofluorescence using a monoclonal antibody specific for the 25-27-kd outer membrane protein of *L. intracellularis*.

SciSearch(R) Cited Ref Sci (Dialog® File 34): (c) 2001 Inst for Sci Info. All rights reserved.

---

2/3,AB/5 (Item 1 from file: 50)

03138144 CAB Accession Number: 952219483

**Characterization of *Lawsonia intracellularis* gen. nov., sp. nov., the obligately intracellular bacterium of porcine proliferative enteropathy.**

McOrist, S.; Gebhart, C. J.; Boid, R.; Barns, S. M.

Department of Veterinary Pathology, Veterinary Field Station, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, UK.

International Journal of Systematic Bacteriology vol. 45 ( 4 ): p.820-825

Publication Year: 1995

ISSN: 0020-7713

Language: English

Document Type: Journal article

A novel bacterium, ileal symbiont intracellularis, obtained from the intestines of pigs with proliferative enteropathy disease, was grown in pure cocultures with tissue cultures of rat cells. An examination of the 16S ribosomal DNA gene sequence revealed that the isolates obtained are members of the delta subdivision of the Proteobacteria and that the sequences of these organisms exhibit 91% similarity with *Desulfovibrio desulfuricans* ATCC 27774. These isolates were homogeneous and differed in cellular morphology, acid fastness, phenotype, electrophoretic protein profile, and habitat from *Desulfovibrio* species. It is concluded that these bacteria belong to a previously undescribed genus and species, for which the name *Lawsonia intracellularis* gen. nov., sp. nov. is proposed. A species-specific recombinant DNA probe, previously cloned, was used to identify the bacterium in tissue culture cells and in the ileal epithelia of pigs with proliferative enteropathy disease. The type strain was designated as NCTC 12656. The organism is pathogenic for pigs and causes proliferative enteropathy lesions in their ilea and colons.

Key words: Lawsonia intracellularis, porcine proliferative enteropathy, ileal symbiont intracellularis, cocultures, 16S ribosomal DNA, Desulfovibrio desulfuricans, NCTC 12656.

known postulates were fulfilled for this organism. 23 ref.

CAB Abstracts (Dialog® File 50): (c) 2001 CAB International. All rights reserved.

---

2/3,AB/6 (Item 1 from file: 180)

**DIALOG Accession Number:** 03069577      **Supplier Number:** 66083011

**New Animal Drugs for Use in Animal Feeds; Ractopamine and Tylosin**

**Volume:** 66    **Issue:** 83    **Page:** 21283

**Citation Number:** 66 FR 21283

**Date:** Monday, April 30, 2001

Federal Register (Dialog® File 180): (c) 2001 format only The DIALOG Corp. All rights reserved.

---

2/3,AB/7 (Item 1 from file: 348)

01270274

**Lawsonia intracellularis proteins, and related methods and materials**

**Title in German:** Lawsonia intracellularis Proteine sowie Methoden und Materialien die diese verwenden

**Title in French:** Proteines de Lawsonia intracellularis et procedes et materiaux relatifs a ces proteines

**Patent Assignee:** Pfizer Products Inc., (2434221), Eastern Point Road, Groton, Connecticut 06340, (US), (Applicant designated States: all)

**Inventor:** Rosey, Everett Lee, Pfizer Central Research, Eastern Point Road, Groton, Connecticut 06340, (US)

**Legal Representative:** Eddowes, Simon et al (87482), Urquhart-Dykes & Lord, 30 Welbeck Street, London W1G 8ER, (GB)

	<b>Patent Number</b>	<b>Kind</b>	<b>Date</b>
<b>Patent</b>	EP 1094070	A2	010425 (Basic)
<b>Application</b>	EP 309125		001017
<b>Priority</b>	US 160922		991022

**Designated States:** AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE

**Extended Designated States:** AL; LT; LV; MK; RO; SI

**International Patent Class:** C07K-014/205; C12N-015/31

### Abstract EP 1094070 A2

Isolated polynucleotide molecules contain a nucleotide sequence that encodes a *L. intracellularis* HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic compositions and assays are described.

**Abstract Word Count:** 40 **Note:**

Figure number on first page: 1

**Language (Publication,Procedural,Application):** English; English; English

### FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200117	864
SPEC A	(English)	200117	25111
Total word count	Document A	25975	
T tal word count	Document B	0	
Total w rd count	Document A + B	25975	



2/3,AB/8 (Item 1 from file: 349)

00757707

**LAWSONIA DERIVED GENE AND RELATED HEMOLYSIN  
POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES  
GENE DERIVE DE LAWSONIA , POLYPEPTIDES, PEPTIDES ET  
PROTEINES D'HEMOLYSINE ET LEURS UTILISATIONS**

**Patent Applicant/Assignee:**

PFIZER PRODUCTS INC, Eastern Point Road, Groton, CT 06340, US, US  
(Residence), US (Nationality), (For all designated states except: US)

AGRICULTURE VICTORIA SERVICES PTY LTD, 475 Mickleham Road,  
Attwood, Victoria 3049, AU, AU (Residence), AU (Nationality), (For all  
designated states except: US)

PIG RESEARCH AND DEVELOPMENT CORPORATION, 3rd Floor, Industry  
House, 10 National Circuit, Barton, Australian Capital Territory 2600, AU, AU  
(Residence), AU (Nationality), (For all designated states except: US)

**Patent Applicant/Inventor:**

PANACCIO Michael, 112 Hill Road, North Balwyn, Victoria 3104, AU, AU  
(Residence), AU (Nationality), (Designated only for: US)

ROSEY Everett Lee, 457 Route 164, Preston, CT 06365, US, US (Residence),  
US (Nationality), (Designated only for: US)

HASSE Detlef, 4 Scullin Court, Sunbury, Victoria 3429, AU, AU (Residence),  
AU (Nationality), (Designated only for: US)

ANKENBAUER Robert Gerard, 104 Castle Hill Road, Pawcatuck, CT 06379,  
US, US (Residence), US (Nationality), (Designated only for: US)

**Legal Representative:**

OLIVE Mark R, Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC  
3000, AU

**Patent and Priority Information (Country, Number, Date):**

**Patent:** WO 200069906 A1 20001123 (WO 0069906)

**Applicati n:** WO 2000AU439 20000511 (PCT/ WO AU0000439 )

**Pri rity Application:** US 99134022 19990513

**Designated States:** AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR  
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE  
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL  
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA  
ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

**Publication Language:** English

**Filing Language:** English

**Fulltext Word Count:** 20844

### English Abstract

The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by *Lawsonia intracellularis* or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from *Lawsonia intracellularis* which encodes an immunogenic hemolysin peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against *Lawsonia intracellularis* and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting *Lawsonia intracellularis* or similar or otherwise related microorganisms.

### French Abstract

La presente invention concerne d'une maniere generale des compositions therapeutiques destinees au traitement et/ou a la prophylaxie de maladies intestinales chez des animaux et des oiseaux, provoquees ou exacerbees par *Lawsonia intracellularis* ou un autre micro-organisme similaire ou associe. L'invention concerne en particulier un nouveau gene derive de *Lawsonia intracellularis* codant pour un peptide, un polypeptide ou une proteine d'hémolysine immunogene, particulierement utiles en tant qu'antigene dans

des preparations vaccinales pour generer chez des animaux hotes une immunité humorale contre *Lawsonia intracellularis* et les agents pathogenes associes. L'invention concerne également des methodes de traitement et/ou de prophylaxie de telles maladies intestinales, ainsi que des agents de diagnostic et des procedes de detection de *Lawsonia intracellularis* ou de micro-organismes similaires ou associes.

PCT Fulltext (Dialog® File 349): (c) 2001 WIPO/MicroPat. All rights reserved.

---

2/3,AB/9 (Item 2 from file: 349)

00757706

**LAWSONIA DERIVED GENE AND RELATED Omph POLYPEPTIDES,  
PEPTIDES AND PROTEINS AND THEIR USES  
GENE DERIVE DE LAWSONIA ET POLYPEPTIDES, PEPTIDES ET  
PROTEINES OMPH APPARENTES, ET LEURS UTILISATIONS**

**Patent Applicant/Assignee:**

PIG RESEARCH AND DEVELOPMENT CORPORATION, 3rd Floor, Industry House, 10 National Circuit, Barton, ACT 2600, AU, AU (Residence), AU (Nationality), (For all designated states except: US)

AGRICULTURE VICTORIA SERVICES PTY LTD, 475 Mickleham Road, Attwood, VIC 3049, AU, AU (Residence), AU (Nationality), (For all designated states except: US)

**Patent Applicant/Inventor:**

HASSE Detlef, 4 Scullin Court, Sunbury, VIC 3429, AU, AU (Residence), AU (Nationality), (Designated only for: US)

PANACCIO Michael, 112 Hill Road, North Balwyn, VIC 3104, AU, AU (Residence), AU (Nationality), (Designated only for: US)

SINISTAJ Meri, 3/60 Gourlay Street, East St. Kilda, VIC 3183, AU, AU (Residence), AU (Nationality), (Designated only for: US)

**Legal Representative:**

OLIVE Mark R, Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000, AU

**Patent and Priority Information (Country, Number, Date):**

**Patent:** WO 200069905 A1 20001123 (WO 0069905)

**Application:** WO 2000AU438 20000511 (PCT/ WO AU0000438 )

**Priority Application:** US 99133986 19990513

**Designated States:** AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR  
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE  
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL  
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA  
ZW

( EP ) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

( OA ) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

( AP ) GH GM KE LS MW SD SL SZ TZ UG ZW

( EA ) AM AZ BY KG KZ MD RU TJ TM

**Publication Language:** English

**Filing Language:** English

**Fulltext Word Count:** 20898

### English Abstract

The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by *Lawsonia intracellularis* or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from *Lawsonia intracellularis* which encodes an immunogenic Omph peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against *Lawsonia intracellularis* and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting *Lawsonia intracellularis* or similar or otherwise related microorganisms.

### French Abstract

La presente invention concerne generalement des compositions therapeutiques permettant de traiter et/ou de prevenir des infections intestinales chez des animaux et des oiseaux, ces infections etant provoquees ou aggravees par *Lawsonia intracellularis* ou tout autre micro-organisme

identique ou apparente. La presente invention concerne en particulier un nouveau gene derive de *Lawsonia intracellularis*, ce gene codant pour un peptide, un polypeptide, ou une proteine OmpH immunogene qui est particulierement utile comme antigene dans des preparations vaccinales et qui confere une immunité humorale contre *Lawsonia intracellularis*, et ses agents pathogenes apparentes, a des hotes animaux. Enfin, la presente invention concerne des methodes permettant de traiter et/ou de prevenir les infections intestinales susmentionnees, ainsi que des agents diagnostiques et des procedures pour detecter *Lawsonia intracellularis* ou tout autre micro-organisme identique ou apparente.

PCT Fulltext (Dialog® File 349): (c) 2001 WIPO/MicroPat. All rights reserved.

---

2/3,AB/10 (Item 3 from file: 349)

00757705

**LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES,  
PEPTIDES AND PROTEINS AND THEIR USES**

**GENE DERIVE DE LAWSONIA, POLYPEPTIDES FLGE, PEPTIDES ET  
PROTEINES ET LEURS UTILISATIONS**

**Patent Applicant/Assignee:**

PFIZER PRODUCTS INC, Eastern Point Road, Groton, CT 06340, US, US  
(Residence), US (Nationality), (For all designated states except: US)

AGRICULTURE VICTORIA SERVICES PTY LTD, 475 Mickleham Road,  
Attwood, VIC 3049, AU, AU (Residence), AU (Nationality), (For all designated  
states except: US)

PIG RESEARCH AND DEVELOPMENT CORPORATION, 3rd Floor, Industry  
House, 10 National Circuit, Barton, ACT 2600, AU, AU (Residence), AU  
(Nationality), (For all designated states except: US)

**Patent Applicant/Inventor:**

PANACCIO Michael, 112 Hill Road, North Balwyn, VIC 3104, AU, AU  
(Residence), AU (Nationality), (Designated only for: US)

ROSEY Everett Lee, 457 Route 164, Preston, CT 06365, US, US (Residence),  
US (Nationality), (Designated only for: US)

SINISTAJ Meri, 3/60 Gourlay Street, East St. Kilda, VIC 3183, AU, AU  
(Residence), AU (Nationality), (Designated only for: US)

HASSE Detlef, 4 Scullin Court, Sunbury, VIC 3429, AU, AU (Residence), AU  
(Nationality), (Designated only for: US)

PARSONS Jim, 11 Kanandah Court, Research, VIC 3095, AU, AU  
(Residence), AU (Nationality), (Designated only for: US)

ANKENBAUER Robert Gerard , 104 Castle Hill Road, Pawcatuck, CT 06379,  
US, US (Residence), US (Nationality), (Designated only for: US)

**Legal Representative:**

OLIVE Mark R, Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC  
3000, AU

**Patent and Priority Information (Country, Number, Date):**

**Patent:** WO 200069904 A1 20001123 (WO 0069904)

**Application:** WO 2000AU437 20000511 (PCT/ WO AU0000437 )

**Priority Application:** US 99133973 19990513

**Designated States:** AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR  
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE  
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL  
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA  
ZW

( EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

( OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

( AP) GH GM KE LS MW SD SL SZ TZ UG ZW

( EA) AM AZ BY KG KZ MD RU TJ TM

**Publication Language:** English

**Filing Language:** English

**Fulltext Word Count:** 21053

**English Abstract**

The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by *Lawsonia intracellularis* or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from *Lawsonia intracellularis* which encodes an immunogenic FlgE peptide, polypeptide or protein that is particularly useful as

an antigen in vaccine preparation for conferring humoral immunity against *Lawsonia intracellularis* and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting *Lawsonia intracellularis* or similar or otherwise related microorganisms.

### French Abstract

La presente invention concerne d'une facon generale des compositions therapeutiques destinees au traitement et/ou a la prophylaxie des maladies intestinales chez les animaux et les oiseaux causees ou aggravees par *Lawsonia intracellularis* ou par des micro-organismes similaires ou apparentes. Cette invention concerne en particulier un gene derive de *Lawsonia intracellularis* codant pour un peptide immunogene FlgE, un polypeptide ou une proteine qui convient particulierement comme antigene dans une preparation de vaccin destine a apporter une immunité humorale contre *Lawsonia intracellularis* et les micro-organismes pathogenes des animaux. La presente invention concerne aussi des methodes destinees au traitement et a la prophylaxie de ces maladies intestinales, des agents diagnostiques et des methodes permettant de detecter *Lawsonia intracellularis* ou des micro-organismes similaires ou apparentes.

PCT Fulltext (Dialog® File 349): (c) 2001 WIPO/MicroPat. All rights reserved.

---

2/3,AB/11 (Item 4 from file: 349)

00757704

**LAWSONIA DERIVED GENE AND RELATED SodC POLYPEPTIDES,  
PEPTIDES AND PROTEINS AND THEIR USES**

**GENE DERIVE DE LAWSONIA ET POLYPEPTIDES, PEPTIDES ET  
PROTEINES SODC ASSOCIES, ET LEURS UTILISATIONS**

**Patent Applicant/Assignee:**

PFIZER PRODUCTS INC, Eastern Point Road, Groton, CT 06340, US, US  
(Residence), US (Nationality), (For all designated states except: US)

PIG RESEARCH AND DEVELOPMENT CORPORATION, 3rd Floor, Industry House, 10 National Circuit, Barton, Australian Capital Territory 2600, AU, AU (Residence), AU (Nationality), (For all designated states except: US)

AGRICULTURE VICTORIA SERVICES PTY LTD, 475 Mickleham Road, Attwood, Victoria 3049, AU, AU (Residence), AU (Nationality), (For all designated states except: US)

**Patent Applicant/Inventor:**

ANKENBAUER Robert Gerard, 104 Castle Hill Road, Pawcatuck, CT 06379, US, US (Residence), US (Nationality), (Designated only for: US)

HASSE Detlef, 4 Scullin Court, Sunbury, Victoria 3429, AU, AU (Residence), AU (Nationality), (Designated only for: US)

PANACCIO Michael, 112 Hill Road, North Balwyn, Victoria 3104, AU, AU (Residence), AU (Nationality), (Designated only for: US)

ROSEY Everett Lee, 457 Route 164, Preston, CT 06365, US, US (Residence), US (Nationality), (Designated only for: US)

WRIGHT Catherine, 49/422 Cardigan Street, Carlton, Victoria 3053, AU, AU (Residence), AU (Nationality), (Designated only for: US)

**Legal Representative:**

OLIVE Mark R, Davies Collison Cave, 1 Little Collins Street, Melbourne, Victoria 3000, AU

**Patent and Priority Information (Country, Number, Date):**

**Patent:** WO 200069903 A1 20001123 (WO 0069903)

**Application:** WO 2000AU436 20000511 (PCT/ WO AU0000436 )

**Priority Application:** US 99133989 19990513

**Designated States:** AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

( EP ) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

( OA ) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

( AP ) GH GM KE LS MW SD SL SZ TZ UG ZW

( EA ) AM AZ BY KG KZ MD RU TJ TM

**Publication Language:** English

**Filing Language:** English



**Fulltext Word Count: 21674**

### **English Abstract**

The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by *Lawsonia intracellularis* or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from *Lawsonia intracellularis* which encodes an immunogenic SodC peptide, polypeptide or protein that is particularly useful as an antigen in vaccine preparation for conferring humoral immunity against *Lawsonia intracellularis* and related pathogens in animal hosts. The present invention is also directed to methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting *Lawsonia intracellularis* or similar or otherwise related microorganisms.

### **French Abstract**

La presente invention porte en general sur des compositions therapeutiques utilisees dans le traitement et/ou la prophylaxie des maladies intestinales chez les animaux et les oiseaux provoques ou exacerbees par *Lawsonia intracellularis* ou similaire ou autre micro-organisme apparente. Cette invention porte notamment sur un nouveau gene derive de *Lawsonia intracellularis* qui code un peptide, polypeptide ou proteine SodC immunogenique qui est notamment utile comme antigene dans la preparation de vaccins en vue de conferer l'immunité humorale contre *Lawsonia intracellularis* et des agents pathogenes apparentes chez des animaux hotes. Cette invention porte egalement sur des procedes de traitement et/ou prophylaxie de ces maladies intestinales, ainsi que sur des agents diagnostiques et sur des procedures de detection de *Lawsonia intracellularis* ou similaire ou autres micro-organismes apparentes.

PCT Fulltext (Dialog® File 349): (c) 2001 WIPO/MicroPat. All rights reserved.

---

2/3,AB/12 (Item 5 from file: 349)

00701137

< i> STAPHYLOCOCCUS AUREUS< /i> GENES AND POLYPEPTIDES  
GENES DE < i> STAPHYLOCOCCUS AUREUS< /i> ET POLYPEPTIDES  
ASSOCIES

**Patent Applicant/Assignee:**

HUMAN GENOME SCIENCES INC, HUMAN GENOME SCIENCES, INC.,  
9410 Key West Avenue, Rockville, MD 20850, US

**Inventor(s):**

BAILEY Camella C, BAILEY, Camella, C., 1753 Kilbourne Place NW,  
Washington, DC 20010, US

CHOI Gil H, CHOI, Gil, H., 11429 Potomac Oaks Drive, Rockville, MD 20850,  
US

**Patent and Priority Information (Country, Number, Date):**

**Patent:** WO 0012678 A2 20000309 (WO 200012678)

**Application:** WO 99US19726 19990831 (PCT/ WO US9919726 )

**Priority Application:** US 9898964 19980901

**Designated States:** AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE  
DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR  
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK  
SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ  
UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB  
GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD  
TG

**Publication Language:** English

**Filing Language:** English

**Fulltext Word Count:** 33507

**English Abstract**

The present invention relates to novel genes from < i> S. aureus< /i> and the polypeptides they encode. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of < i> S. aureus< /i> polypeptide activity. The invention additionally relates to diagnostic methods for detecting < i> Staphylococcus< /i> nucleic acids,

polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by *Staphylococcus*.

### French Abstract

La presente invention concerne de nouveaux genes provenant de *S. aureus* et les polypeptides qu'ils codent. On decrit egalement des vecteurs, des cellules hotes, des anticorps et des procedes de recombinaison utilises pour produire ces derniers; ainsi que des procedes de criblage permettant d'identifier des agonistes et des antagonistes de l'activite du polypeptide *S. aureus*. L'invention concerne en outre des procedes de diagnostic utiles pour detecter des acides nucleiques, des polypeptides et des anticorps de *Staphylococcus* dans un echantillon biologique, ainsi que de nouveaux vaccins permettant de prevenir ou d'attenuer l'infection par le *Staphylococcus*.

PCT Fulltext (Dialog® File 349): (c) 2001 WIPO/MicroPat. All rights reserved.

---

2/3,AB/13 (Item 1 from file: 357)

0213848 DBA Accessi n No.: 97-08969 PATENT

**Vaccine for treating or preventing infection by *Lawsonia intracellularis* - GroEL or GroES protein, etc., or DNA sequence for use as a pig recombinant vaccine or nucleic acid vaccine**

**Author:** Panaccio M; Hasse D

**Corporate Source:** Melbourne, Victoria, Australia; Barton, Australian Capital Territory, Australia.

**Patent Assignee:** Daratech; Pig-Research-Development 1997

**Patent Number:** WO 9720050 **Patent Date:** 970605 **WPI Accession No.:** 97-310605 ( 9728 )

**Priority Application Number:** AU 956911 **Application Date:** 951130

**National Application Number:** WO 96AU767 **Application Date:** 961129

**Language:** English

**Abstract:** A new vaccine composition for prevention or therapy of animal or bird (particularly pig) infection by *Lawsonia intracellularis* or a related strain contains an immunogenic non-pathogenic form of *L. intracellularis*, e.g. an attenuated strain or formaldehyde-killed preparation, or an immunogenic peptide, protein (optionally recombinant), carbohydrate, lipid or nucleic acid from the strain. A refolding or heat shock protein (GroEL or GroES protein, preferred), a flagellum basal body rod protein, S-adenosylmethionine:tRNA-ribosyltransferase-isomerase, autolysin (EC-3.4.24.38), enoyl-(acyl-carrier-protein)-reductase or a glucarate transporter or derivative may be present. DNA sequences encoding several of these components are claimed, and may be used to produce recombinant vaccines or as nucleic acid vaccines. The vaccines may be used e.g. to prevent proliferative enteropathy in pigs. (94pp)

Derwent Biotechnology Abs (Dialog® File 357): (c) 2001 Derwent Publ Ltd. All rights reserved.

---

2/3,AB/14 (Item 1 from file: 399)

134321599 CA: 134(23)321599h PATENT

**Cloning of Lawsonia genes htrA, ponA, hypC, lysS, ycfW, abc1, and omp100, their encoded proteins or peptides and therapeutic use in diagnosis and as vaccine**

**Inventor (Author):** Rosey, Everett Lee

**Location:** USA

**Assignee:** Pfizer Products Inc.

**Patent:** European Pat. Appl. ; EP 1094070 A2 **Date:** 20010425

**Application:** EP 2000309125 (20001017) \*US PV160922 (19991022)

**Pages:** 80 pp.

**CODEN:** EPXXDW

**Language:** English

**Class:** C07K-014/205A; C12N-015/31B

**Designated Countries:** AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO

CA SEARCH(R) (Dialog® File 399): (c) 2001 AMERICAN CHEMICAL SOCIETY. All rights reserved.

---

2/3,AB/15 (Item 2 from file: 399)

134014022 CA: 134(2)14022f PATENT

**Laws nia-derived gene ompH and related outer membrane protein H polypeptides, peptides and proteins and their uses for diagnosis and treatment of avian and porcine infections**

**Inventor (Author):** Hasse, Detlef; Panaccio, Michael; Sinistaj, Meri

**Location:** Australia

**Assignee:** Pig Research and Development Corporation; Agriculture Victoria Services Pty Ltd

**Patent:** PCT International ; WO 200069905 A1 **Date:** 20001123

**Application:** WO 2000AU438 (20000511) \*US PV133986 (19990513)

**Pages:** 85 pp.

**CODEN:** PIXXD2

**Language:** English

**Class:** C07K-014/195A; C07H-021/04B; A61K-039/02B; A61P-001/00B

**Designated Countries:** AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

**Designated Regional:** GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

CA SEARCH(R) (Dialog® File 399): (c) 2001 AMERICAN CHEMICAL SOCIETY. All rights reserved.

---

2/3,AB/16 (Item 3 from file: 399)

134001364 CA: 134(1)1364u PATENT

**Laws nia-derived gene tlyA and related hemolysin polypeptides, peptides and proteins and their uses for diagnosis and treatment of avian and porcine infections**

**Inventor (Author):** Panaccio, Michael; Rosey, Everett Lee; Hasse, Detlef; Ankenbauer, Robert Gerard

**Location:** USA

**Assignee:** Pfizer Products Inc; Agriculture Victoria Services Pty Ltd; Pig Research and Development Corporation

**Patent:** PCT International ; WO 200069906 A1 **Date:** 20001123

**Application:** WO 2000AU439 (20000511) \*US PV134022 (19990513)

**Pages:** 86 pp.

**CODEN:** PIXXD2

**Language:** English

**Class:** C07K-014/195A; C07H-021/04B; A61K-039/02B; A61P-001/00B

**Designated Countries:** AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

**Designated Regional:** GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

CA SEARCH(R) (Dialog® File 399): (c) 2001 AMERICAN CHEMICAL SOCIETY. All rights reserved.

---

2/3,AB/17 (Item 4 from file: 399)

133359825 CA: 133(26)359825w PATENT

**Lawsonia-derived gene flgE and related flagellar hook polypeptides, peptides and proteins and their uses for diagnosis and treatment of avian and porcine infections**

**Inventor (Author):** Panaccio, Michael; Rosey, Everett Lee; Sinistaj, Meri; Hasse, Detlef; Parsons, Jim; Ankenbauer, Robert Gerard

**Location:** USA

**Assignee:** Pfizer Products Inc.; Agriculture Victoria Services Pty Ltd; Pig Research and Development Corporation

**Patent:** PCT International ; WO 200069904 A1 **Date:** 20001123

**Application:** WO 2000AU437 (20000511) \*US PV133973 (19990513)

**Pages:** 97 pp.

**CODEN:** PIXXD2

**Language:** English

**Class:** C07K-014/195A; C07H-021/04B; A61K-039/02B; A61P-001/00B

**Designated Countries:** AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

**Designated Regional:** GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

CA SEARCH(R) (Dialog® File 399): (c) 2001 AMERICAN CHEMICAL SOCIETY. All rights reserved.

---



2/3,AB/18 (Item 5 from file: 399)

133359824 CA: 133(26)359824v PATENT

**Lawsonia-derived gene sodC and related superoxide dismutase polypeptides, peptides and proteins and their uses for diagnosis and treatment of avian and porcine infections**

**Inventor (Author):** Ankenbauer, Robert Gerard; Hasse, Detlef; Panaccio, Michael; Rosey, Everett Lee; Wright, Catherine

**Location:** USA

**Assignee:** Pfizer Products, Inc.; Pig Research and Development Corp.; Agriculture Victoria Services Pty., Ltd.

**Patent:** PCT International ; WO 200069903 A1 **Date:** 20001123

**Application:** WO 2000AU436 (20000511) \*US PV133989 (19990513)

**Pages:** 85 pp.

**CODEN:** PIXXD2

**Language:** English

**Class:** C07K-014/195A; C07H-021/04B; A61K-039/02B; A61P-001/00B

**Designated Countries:** AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

**Designated Regional:** GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

CA SEARCH(R) (Dialog® File 399): (c) 2001 AMERICAN CHEMICAL SOCIETY. All rights reserved.

---

2/3,AB/19 (Item 6 from file: 399)

127094116 CA: 127(7)94116h PATENT

**Lawsonia intracellularis immunogenic components identification, DNA sequences, and uses for animal intestine infection vaccine or diagnosis**

**Inventor (Author):** Panaccio, Michael; Hasse, Detlef

**Location:** Australia

**Assignee:** Daratech Pty. Ltd.; Pig Research and Development Corporation; Panaccio, Michael; Hasse, Detlef

**Patent:** PCT International ; WO 9720050 A1 **Date:** 19970605

**Application:** WO 96AU767 (19961129) \*AU 956910 (19951130) \*AU 956911 (19951130)

**Pages:** 94 pp.

**CODEN:** PIXXD2

**Language:** English

**Class:** C12N-015/31A; A61K-039/02B; A61K-039/106B

**Designated Countries:** AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

**Designated Regional:** KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

CA SEARCH(R) (Dialog® File 399): (c) 2001 AMERICAN CHEMICAL SOCIETY. All rights reserved.

---

2/3,AB/20 (Item 1 from file: 654)

02928383

Utility

**LAWSONIA INTRACELLULARIS CULTIVATION, ANTI-LAWSONIA  
INTRACELLULARIS VACCINES AND DIAGNOSTIC AGENTS**

[ Bacteria strain ATCC No.55783 are incubated in an oxygen concentration of from about 0 percent to about 18 percent, agitating the bacteria in suspension veterinary medicine ]

**Patent Number:** 5,885,823

ISSUED: March 23, 1999 (19990323)

**Inventor:** Knittel Jeffrey P Ames IA (Iowa) US (United States of America)

Roof Michael B Ames IA (Iowa) US (United States of America)

**Assignee:** NOBL Laboratories Inc (A U.S. Company or Corporation)  
Sioux Center IA (Iowa) US (United States of America)

[Assignee Code(s): 44486]

**Application** 8-658,194

**Number:** FILED: June 04, 1996 (19960604)

This application is a continuation-in-part of U.S. patent application Ser. No. 08-465,337 (U.S. Pat. No. 5,714,375) filed Jun. 5, 1995.

**Full Text:** 1488 lines

**ABSTRACT**

A method for large scale cultivation and attenuation of L. intracellula bacteria by inoculating cells with L. intracellularis bacteria to infec the cells, incubating the infected cells in a reduced oxygen concentrat and maintaining the infected cells in suspension. Anti-L. intracellular vaccines are prepared from cultures grown in suspension. Diagnostic age are also disclosed.

US PAT.FULL. (Dialog® File 654): (c) format only 2001 The Dialog Corp. All rights reserved.

© 2001 The Dialog Corporation plc

## Processing your request...

### Dialog Index Results

---

Your select statement is 'S (LAWSONIA OR  
ILEAL(W)SYMBIANT)(2N)INTRACELLULAR?S' in databases ALLMEDPH.

☒ Select All

☒ Clear Selections





<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	41
<input type="checkbox"/> 9:	<u>Business &amp; Industry(TM)</u>	2
<input type="checkbox"/> 10:	<u>AGRICOLA</u>	47
<input type="checkbox"/> 16:	<u>Gale Group PROMT® (1990 - present)</u>	4
<input type="checkbox"/> 19:	<u>Chemical Industry Notes (CIN)</u>	1
<input type="checkbox"/> 20:	<u>World Reporter</u>	1
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	66
<input type="checkbox"/> 35:	<u>Dissertation Abstracts Online</u>	1
<input type="checkbox"/> 50:	<u>CAB ABSTRACTS</u>	112
<input type="checkbox"/> 65:	<u>Inside Conferences</u>	39
<input type="checkbox"/> 71:	<u>Elsevier Biobase</u>	14
<input type="checkbox"/> 73:	<u>EMBASE® (1974-present)</u>	20
<input type="checkbox"/> 76:	<u>Life Sciences Collection</u>	15
<input type="checkbox"/> 77:	<u>Conference Papers Index</u>	2
<input type="checkbox"/> 88:	<u>Gale Group Business A.R.T.S. (SM)</u>	1
<input type="checkbox"/> 94:	<u>JICST-EPlus - Japanese Science &amp; Technology</u>	3
<input type="checkbox"/> 98:	<u>General Science Abstracts/Fulltext</u>	1
<input type="checkbox"/> 112:	<u>UBM Industry News(TM)</u>	5

<input type="checkbox"/> 129:	<u>Pharmaceutical and Healthcare Industry News Database (PHIND) - weekly</u>	3
<input type="checkbox"/> 143:	<u>Wilson Biological &amp; Agricultural Index</u>	6
<input type="checkbox"/> 144:	<u>PASCAL</u>	11
<input type="checkbox"/> 155:	<u>MEDLINE® (1966-present)</u>	44
<input type="checkbox"/> 156:	<u>TOXLINE®</u>	1
<input type="checkbox"/> 158:	<u>DIOGENES® FDA Regulatory Updates</u>	1
<input type="checkbox"/> 159:	<u>CANCERLIT®</u>	1
<input type="checkbox"/> 162:	<u>CAB HEALTH</u>	6
<input type="checkbox"/> 180:	<u>Federal Register</u>	6
<input type="checkbox"/> 203:	<u>AGRIS International</u>	39
<input type="checkbox"/> 266:	<u>Federal Research in Progress (FEDRIP)</u>	4
<input type="checkbox"/> 285:	<u>BioBusiness®</u>	3
<input type="checkbox"/> 340:	<u>CLAIMS®/U.S. Patents</u>	4
<input type="checkbox"/> 348:	<u>European Patents Fulltext</u>	13
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	30
<input type="checkbox"/> 351:	<u>Derwent World Patents Index</u>	11
<input type="checkbox"/> 357:	<u>Derwent Biotechnology Abstracts</u>	2
<input type="checkbox"/> 399:	<u>CA SEARCH® - Chemical Abstracts® (1967- present)</u>	18
<input type="checkbox"/> 440:	<u>Current Contents Search®</u>	97
<input type="checkbox"/> 636:	<u>Gale Group Newsletter Database(TM)</u>	3
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1990-present)</u>	14

There are **39** databases matching your statement '**S (LAWSONIA OR ILEAL(W)SYMBIANT)(2N)INTRACELLULAR?S**'.

☒ **Select All**
☒ **Clear Selections**



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ▾ for

Go Clear

Limits Preview/Index History Clipboard

Display Abstract ▾

Save

Text

Order

Add to Clipboard

Entrez  
PubMed

1: Res Vet Sci 1995  
Nov;59(3):255-60

Related Article  
Box

**Entry of the bacterium ileal symbiont  
intracellularis into cultured enterocytes and its  
subsequent release.**

PubMed  
Services

**McOrist S, Jasni S, Mackie RA, Berschneider HM,  
Rowland AC, Lawson GH.**

Department of Veterinary Pathology, University of  
Edinburgh, Veterinary Field Station, Easter Bush,  
Midlothian.

Related  
Resources

Separate suspensions of two strains of ileal symbiont (I  
intracellularis, an obligate intracellular bacterium and the  
causative agent of porcine proliferative enteropathy, were  
added to 40 or 80 per cent confluent monolayers of  
established cultures of rat (IEC-18) or pig enterocytes  
(IPEC-J2). Peak numbers of intracellular organisms were  
detected within the enterocytes six days later, but no  
cytopathic effects were evident. After an initial close  
association with the cell membrane of the enterocytes,  
single bacteria were internalised after three hours with  
membrane-bound vacuoles. The formation of an

membranes bound vacuoles. The formation of an electron-dense projection between cell membranes and external bacteria was only evident if the bacterial suspensions were centrifuged on to the monolayers. The release of internalised bacteria into the cytoplasm, with the breakdown and loss of membrane-bound vacuoles, was also evident three hours after infection. Internalised bacteria were associated with, but not observed within, coated membrane pits. Mitochondria were closely associated with internalised vacuoles and with released bacteria. Two to six days after infection, multiplication of the bacteria free in the cytoplasm was frequently observed. In infected cells six days after the inoculation of monolayers, groups of bacteria were found within large balloon-like, cytoplasmic protrusions, and the subsequent release of bacteria from the monolayer provided a means of bacterial exit from the cells. Many events in the in vitro culture model closely resembled events observed at the cellular level in animals infected with IS intracellularis. The model provides a useful basis for investigating the pathogenetic mechanisms of this bacterium.

PMID: 8588102 [PubMed - indexed for MEDLINE]

---

Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)





PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ▾ for

Go Clear

Limits Preview/Index History Clipboard

Display Abstract ▾

Save

Text

Order

Add to Clipboard

Entrez  
PubMed

☐ 1: Int J Syst Bacteriol 1995  
Oct;45(4):820-5

Related Articles, Books  
Nucleotides

**Characterization of *Lawsonia intracellularis* gen.  
nov., sp. nov., the obligately intracellular  
bacterium of porcine proliferative enteropathy**

PubMed  
Services

**McOrist S, Gebhart CJ, Boid R, Barns SM.**

Department of Veterinary Pathology, University of  
Edinburgh, Easter Bush, Midlothian, United Kingdom.

Related  
Resources

A novel obligately intracellular bacterium, ileal symbiont *intracellularis*, which was obtained from the intestines of pigs with proliferative enteropathy disease, was grown in pure cocultures with tissue cultures of rat cells. An examination of the 16S ribosomal DNA gene sequence revealed that the isolates which we obtained are members of the delta subdivision of the Proteobacteria and that sequences of these organisms exhibit a level of similarity 91% with the sequence of *Desulfovibrio desulfuricans* ATCC 27774. These isolates were homogeneous and differed in cellular morphology, acid fastness, phenotypic electrophoretic protein profile, and habitat from *Desulfovibrio* species. On the basis of the results of an

described species. On the basis of the results of an integrated study of the phenotype and genotype of a consistent morphological entity found in particular porc cells and associated with a well-defined clinical condition we concluded that these bacteria belong to a previously undescribed genus and species, for which we propose the name *Lawsonia intracellularis* gen. nov., sp. nov. A species-specific recombinant DNA probe was cloned previously, and this probe was used to identify the bacterium in tissue culture cells and in the ileal epithelium of pigs with proliferative enteropathy disease. Coculture of the organism with a rat enterocyte cell line allowed us to designate strain NCTC 12656 the type strain and to describe the new genus and species. The organism which we cultured is pathogenic for pigs and causes proliferative enteropathy lesions in their ilea and colons, and Koch's postulates were fulfilled for this organism.

PMID: 7547305 [PubMed - indexed for MEDLINE]

---


Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ▾ for

Go Clear

Limits Preview/Index History Clipboard

Display Abstract ▾

Save

Text

Order

Add to Clipboard

Entrez  
PubMed

1: Vet Microbiol 1995  
Aug;45(4):339-50

Related Articles, Books  
LinkC

## Infection of cultured rat enterocytes by *Ileal symbiont intracellularis* depends on host cell function and actin polymerisation.

PubMed  
Services

Lawson GH, Mackie RA, Smith DG, McOrist S.

Department of Veterinary Pathology, University of  
Edinburgh, Easter Bush, Midlothian, UK.

Related  
Resources

The mechanisms of entry of *Ileal symbiont intracellularis* into IEC-18 rat enterocyte cells and subsequent bacter proliferation were examined in centrifuge-assisted and static infections. Live, oxygen or neomycin damaged, and formalin killed bacteria, each rapidly entered viable cell. Live or damaged bacteria did not enter cells nor proliferate within cells after static infection of cells cooled to 5 degrees C. Infection of cells was greatly reduced at 20 degrees or 32 degrees compared to infection at 37 degrees C. Centrifuge-assisted infection was also reduced by chilling the cells. Cytochalasin D but not B inhibited the entry process indicating an actin-dependent infection although other pathways may

actin dependent infection, although other pathways may also be involved in centrifuge-assisted infections. Drugs capable of modifying cell membrane charge, heparin receptors or trypsin-labile proteins were all inactive in preventing or enhancing infection. We therefore conclude that infection of enterocytes by IS intracellularis is dependent on host cell activity and actin polymerization but is independent of bacterial viability.

PMID: 7483247 [PubMed - indexed for MEDLINE]

---


Display	Abstract ▼	Save	Text	Order	Add to Clipboard
---------	------------	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed  for

Go Clear

Limits Preview/Index History Clipboard

Display Abstract

Save

Text

Order

Add to Clipboard

Entrez  
PubMed

☐ 1: J Clin Microbiol 1995  
May;33(5):1314-7

Related Articles, Books  
LinkC

FREE full text article at  
[jcm.asm.org](http://jcm.asm.org)

## Antimicrobial susceptibility of ileal symbiont intracellularis isolated from pigs with proliferative enteropathy.

PubMed  
Services

McOrist S, Mackie RA, Lawson GH.

Department of Veterinary Pathology, University of  
Edinburgh, Midlothian, United Kingdom.

Related  
Resources

Proliferative enteropathy is caused by the microaerophilic obligate intracellular bacterium ileal symbiont (IS) intracellularis. Treatment of this disease is problematic because of the lack of in vivo or in vitro data on the activities of antimicrobial agents. A new procedure for determining the susceptibility of IS intracellularis was developed by using a tissue culture system which promotes the in vitro multiplication of this organism. Nineteen antimicrobial agents were evaluated in triplicate culture for their intracellular and extracellular activities against up to three IS intracellularis strains isolated from pigs with proliferative enteropathy. The MIC was defined as

the lowest concentration which prevented multiplication 99% of the IS intracellularis isolates. Penicillin, erythromycin, difloxacin, virginiamycin, and chlortetracycline were the most active compounds tested all with MICs of  $\leq 1$  microgram/ml. Tiamulin and tilmicosin were the next most active compounds, with MICs of  $\leq 4$  micrograms/ml. The MICs of aminoglycosides were generally  $> 32$  micrograms/ml. Both lincomycin and tylosin were relatively inactive against the IS intracellularis strains tested, with MICs of 32 and 64 micrograms/ml, respectively. These results indicate that some compounds capable of intracytoplasmic accumulation and blocking bacterial protein synthesis were active against IS intracellularis strains isolated from pigs with proliferative enteropathy. The in vitro cultivation system shows promise as a method for studying the interaction between IS intracellularis and antimicrobial agents and screening new antibiotics for use in therapy.

PMID: 7615747 [PubMed - indexed for MEDLINE]

---


Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ▾ for \_\_\_\_\_

Go Clear

Limits Preview/Index History Clipboard

Display Abstract ▾

Save

Text

Order

Add to Clipboard

Entrez  
PubMed

☐ 1: Int J Syst Bacteriol 1993  
Jul;43(3):533-8

Related Articles, Books  
Nucleotides

**Ileal symbiont intracellularis, an obligate  
intracellular bacterium of porcine intestines  
showing a relationship to Desulfovibrio species**

PubMed  
Services

Gebhart CJ, Barns SM, McOrist S, Lin GF, Lawson G

Department of Veterinary Pathobiology, College of  
Veterinary Medicine, University of Minnesota St. Paul  
55108.

Related  
Resources

A new genus and species of obligate intracellular-bacterium found in porcine intestines are described. Growth on an bacteriological medium deprived of living cells has not been demonstrated. The organism has been grown intracellularly in cell culture. The 16S rRNA gene sequence data, DNA probe results, and microscopic observations provide evidence that these bacteria differ from those in other described genera and that they belong to the delta subdivision of the class Proteobacteria. We have amplified and sequenced the 16S ribosomal DNA of four preparations of the intracellular bacterium from pigs. From this intracellular organisms were released and purified

Thus, intracellular organisms were released and purified from the infected cells without culture techniques. After DNA purification, the polymerase chain reaction with primers complementary to highly conserved eubacterial sequences was used to amplify regions of 16S ribosomal DNA which were subsequently cloned (in some cases) and sequenced directly by standard techniques. The sequences obtained from each preparation were identical and were most similar to that of a sulfate-reducing proteobacterium, *Desulfovibrio desulfuricans* ATCC 277 (91% similarity). An oligonucleotide probe complementary to a hypervariable region of the 16S rRNA sequence of bacterium hybridized with intracellular organisms obtained from porcine intestines. The bacterium is a gram-negative curved rod with tapered ends. It multiplies intracellularly in the cytoplasm of ileal epithelial cells by septation. The vernacular name Ileal symbiont (IS) intracellularis is proposed for this bacterium. The type strain of IS intracellularis is strain 1482/89 grown in cell culture from a pig affected by proliferative enteropathy. It is deposited in the National Collection of Type Cultures, Colindale, London, as NCTC 12656.

PMID: 8347512 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Save	Text	Order	Add to Clipboard
---------	----------	---	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)





PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ▾ for

Go Clear

Limits Preview/Index History Clipboard

Display Abstract ▾

Save

Text

Order

Add to Clipboard

Entrez  
PubMed

☐ 1: J Clin Microbiol 1993  
May;31(5):1136-42

Related Articles, Books  
Link

## Intracellular bacteria of porcine proliferative enteropathy: cultivation and maintenance in vitro.

PubMed  
Services

Lawson GH, McOrist S, Jasni S, Mackie RA.

Department of Veterinary Pathology, Royal Dick School Veterinary Studies, University of Edinburgh, Midlothian United Kingdom.

Related  
Resources

An obligate intracellular bacterium was isolated from the intestines of all 10 cases of porcine proliferative enteropathy from four different pig farms. The organism grew in a rat enterocyte cell line (IEC-18) and was maintained over 20 passages. The growth of the bacterium was assessed by immunostaining of cells exposed to infection. Infection was not associated with morphological cell change, and growth was confined to cells infected at the time of each transfer of infection and the progeny of these cells. The bacterium is a microaerophilic, cell dependent, curved or rod-shaped, gram-negative bacillus that multiplies freely in the enterocyte cytoplasm. Cell

that multiplies freely in the enterocyte cytoplasm. Cell cultures containing the intracellular bacteria appear to be free of other microorganisms, including chlamydiae and viruses.

PMID: 8501214 [PubMed - indexed for MEDLINE]

---

Display	Abstract <input type="button" value="v"/>	Save	Text	Order	Add to Clipboard
---------	---	------	------	-------	------------------

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)